CN101743325B - Apo(a)基因中的多态性预测对乙酰水杨酸治疗的反应性 - Google Patents

Apo(a)基因中的多态性预测对乙酰水杨酸治疗的反应性 Download PDF

Info

Publication number
CN101743325B
CN101743325B CN200880024226.8A CN200880024226A CN101743325B CN 101743325 B CN101743325 B CN 101743325B CN 200880024226 A CN200880024226 A CN 200880024226A CN 101743325 B CN101743325 B CN 101743325B
Authority
CN
China
Prior art keywords
polymorphism
purposes
nucleic acid
acetylsalicylic acid
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880024226.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101743325A (zh
Inventor
保罗·里德克尔
丹尼尔·查斯曼
道夫·史夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Applied Biosystems Inc
Original Assignee
Brigham and Womens Hospital Inc
Applera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Applera Corp filed Critical Brigham and Womens Hospital Inc
Publication of CN101743325A publication Critical patent/CN101743325A/zh
Application granted granted Critical
Publication of CN101743325B publication Critical patent/CN101743325B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
CN200880024226.8A 2007-05-09 2008-05-09 Apo(a)基因中的多态性预测对乙酰水杨酸治疗的反应性 Active CN101743325B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91685807P 2007-05-09 2007-05-09
US60/916,858 2007-05-09
PCT/US2008/005986 WO2008140776A1 (en) 2007-05-09 2008-05-09 Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment

Publications (2)

Publication Number Publication Date
CN101743325A CN101743325A (zh) 2010-06-16
CN101743325B true CN101743325B (zh) 2014-07-09

Family

ID=40002550

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880024226.8A Active CN101743325B (zh) 2007-05-09 2008-05-09 Apo(a)基因中的多态性预测对乙酰水杨酸治疗的反应性

Country Status (7)

Country Link
US (6) US7943317B2 (https=)
EP (1) EP2150627B1 (https=)
JP (2) JP5601685B2 (https=)
CN (1) CN101743325B (https=)
BR (1) BRPI0811309B1 (https=)
CA (1) CA2686874C (https=)
WO (1) WO2008140776A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2686874C (en) * 2007-05-09 2021-10-19 The Brigham And Women's Hospital, Inc Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment
WO2013080227A1 (en) * 2011-11-28 2013-06-06 Decode Genetics Ehf Genetic variants useful for risk assessment of arterial disease
US20150227678A1 (en) * 2014-02-09 2015-08-13 Lane Bernard SCHEIBER Method to represent the nucleotide elements of a dna sequence as numerical elements to include adenine being assigned the value one, guanine being assigned the value two, cytosine being assigned the value three, and thymine being assigned the value four

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293510A1 (en) * 2000-06-22 2003-03-19 Takeda Chemical Industries, Ltd. Novel polypeptide and its dna

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1806867C3 (de) * 1968-11-04 1974-07-18 Byk-Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung substituierter 4-Hydroxy pyrimidine
CA2941594C (en) * 2002-12-20 2021-07-06 Celera Corporation Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CA2518956A1 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
CA2547072C (en) * 2003-11-26 2015-06-23 Applera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
CA2566257A1 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient
ATE480229T1 (de) * 2005-05-24 2010-09-15 Flamel Tech Sa Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
WO2008132763A2 (en) * 2007-04-30 2008-11-06 Decode Genetics Ehf Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
CA2686874C (en) 2007-05-09 2021-10-19 The Brigham And Women's Hospital, Inc Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293510A1 (en) * 2000-06-22 2003-03-19 Takeda Chemical Industries, Ltd. Novel polypeptide and its dna

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEUWISSEN THE ET.AL.Fine mapping of quantitative trait loci using linkage disequilibria with closely linked marker loci..《GENETICS》.2000,421-430. *
张奎星等.多基因遗传病基因研究的策略和方法.《生理科学进展》.2001,215-219. *

Also Published As

Publication number Publication date
BRPI0811309B1 (pt) 2022-03-03
US20110206667A1 (en) 2011-08-25
WO2008140776A1 (en) 2008-11-20
EP2150627A1 (en) 2010-02-10
US7943317B2 (en) 2011-05-17
JP2014036674A (ja) 2014-02-27
US20140024623A1 (en) 2014-01-23
US20150284799A1 (en) 2015-10-08
EP2150627B1 (en) 2013-09-11
US11697850B2 (en) 2023-07-11
CN101743325A (zh) 2010-06-16
CA2686874C (en) 2021-10-19
CA2686874A1 (en) 2008-11-20
US20170335394A1 (en) 2017-11-23
BRPI0811309A2 (pt) 2020-09-15
EP2150627A4 (en) 2011-02-23
JP5601685B2 (ja) 2014-10-08
JP2010528262A (ja) 2010-08-19
US20090004187A1 (en) 2009-01-01
US10550433B2 (en) 2020-02-04
US20200248262A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
Paré et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women
EP2663656B1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment
Jia et al. Renin–Angiotensin–Aldosterone System Gene Polymorphisms and Coronary Artery Disease: Detection of Gene-Gene and Gene-Environment Interactions
Lu et al. TGFB1 genetic polymorphisms and coronary heart disease risk: a meta-analysis
Wirtwein et al. Relationship between selected DNA polymorphisms and coronary artery disease complications
US11697850B2 (en) Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
Tarighi et al. Association between two common polymorphisms of vitamin D binding protein and the risk of coronary artery disease: a case-control study
Li et al. Analysis of ADAM17 polymorphisms and susceptibility to sporadic abdominal aortic aneurysm
Koch et al. Polymorphisms in thrombospondin genes and myocardial infarction: a case–control study and a meta-analysis of available evidence
Kondapalli et al. MMP 1 circulating levels and promoter polymorphism in risk prediction of coronary artery disease in asymptomatic first degree relatives
Pereira et al. Genetic risk score and cardiovascular mortality in a southern european population with coronary artery disease
Kallel et al. Polymorphisms of the NOS3 gene and risk of myocardial infarction in the Tunisian population
Koubaa et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome
Aragonès et al. Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study
JP2010528262A5 (https=)
Zhong et al. Monocyte chemoattractant protein-1-2518 G/A polymorphism, plasma levels, and premature stable coronary artery disease
Pérez-Hernández et al. Protective role of DDAH2 (rs805304) gene polymorphism in patients with myocardial infarction
Vargas-Alarcón et al. ABO gene polymorphisms are associated with acute coronary syndrome and with plasma concentration of HDL-cholesterol and triglycerides
Yaghoubi et al. T-786C single-nucleotide polymorphism (SNP) of endothelial nitric oxide synthase gene and serum level of vascular endothelial relaxant factor (VERF) in non-diabetic patients with coronary artery disease
Liu et al. β-fibrinogen haplotypes and the risk for cardiovascular disease in a dialysis cohort
WO2013061342A1 (en) Variants conferring risk of intracranial aneurysm and abdominal aortic aneurysm
Abessolo et al. Enzymatic and genetic polymorphisms of paraoxonase-1 in the Gabonese population: the relation to lipid parameters in patients with diabetes
Yousef et al. GLUL rs10911021 polymorphism and risk of coronary artery disease among Egyptian individuals
Song et al. A case-control study of the relationship between SLC22A3-LPAL2-LPA gene cluster polymorphism and coronary artery disease in the Han Chinese Population
Caamaño et al. Factor XII 46C→ T gene polymorphism in Chilean subjects with coronary artery disease and controls

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant